Ecteinascidin 722

Drug Profile

Ecteinascidin 722

Alternative Names: ET 722

Latest Information Update: 21 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer PharmaMar
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 21 Jul 2009 Discontinued - Preclinical for Cancer in Spain (Parenteral)
  • 08 Oct 1999 ET 722 is now called ecteinascidin 722
  • 08 Oct 1999 Suspended-Preclinical for Cancer in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top